Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates